CureVac Establishes U.S. Operations
News Sep 15, 2015
Headquartered in Tϋbingen, Germany, where CureVac was founded in 2000 as a spinoff of the University, the expansion into the U.S. extends the company’s footprint into one of the world’s preeminent biotechnology hubs. The US subsidiary will be headed by Karen Slobod, MD, as managing director, formerly Head of the Maternal Immunization Franchise at Novartis Vaccines, and will primarily focus on development activities involving CureVac’s rapidly growing pipeline of mRNA-based prophylactic vaccines, which include programs targeting Rotavirus, RSV, HIV, and influenza virus in collaborations with the Bill & Melinda Gates Foundation, IAVI and Johnson & Johnson. Additionally, the U.S. operations will enable CureVac to more directly engage the U.S. pharmaceutical and investor communities.
Ingmar Hoerr, Ph.D., co-founder and CEO of CureVac, commented, “Expansion into the U.S. is an important step in CureVac’s corporate and clinical growth as it will enable us to capitalize on the numerous research and business opportunities related to our industry-leading mRNA technology platform. As such our U.S. office will provide an important base for CureVac to extend our U.S. interest, while enhancing our development capabilities, particularly those targeting mRNA-based prophylactic vaccines.”
CureVac’s technology utilizes natural, chemically unmodified mRNA to develop a broad range of therapeutic candidates in cancer immunotherapies and prophylactic vaccines as well as molecular therapy. To date, CureVac has validated its approach in numerous clinical trials, including an ongoing Phase IIb study in prostate cancer. A recent study demonstrated that CureVac’s mRNAs are also able to raise relevant protein levels without stimulating an unwanted immune reaction and achieved meaningful biological responses.
SMi Presents the 2nd Annual Conference: Injectable Drug Delivery 2019
May 15 - May 16, 2019